EP2770066A3 - Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2 - Google Patents

Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2 Download PDF

Info

Publication number
EP2770066A3
EP2770066A3 EP14161006.3A EP14161006A EP2770066A3 EP 2770066 A3 EP2770066 A3 EP 2770066A3 EP 14161006 A EP14161006 A EP 14161006A EP 2770066 A3 EP2770066 A3 EP 2770066A3
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
nucleic acid
detecting mutations
jak2 nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14161006.3A
Other languages
German (de)
English (en)
Other versions
EP2770066A2 (fr
EP2770066B1 (fr
Inventor
Maher Albitar
Wanlong Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quest Diagnostics Investments LLC
Original Assignee
Quest Diagnostics Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Investments LLC filed Critical Quest Diagnostics Investments LLC
Priority to EP16158591.4A priority Critical patent/EP3093350B1/fr
Priority to EP19180822.9A priority patent/EP3572530B1/fr
Publication of EP2770066A2 publication Critical patent/EP2770066A2/fr
Publication of EP2770066A3 publication Critical patent/EP2770066A3/fr
Application granted granted Critical
Publication of EP2770066B1 publication Critical patent/EP2770066B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP14161006.3A 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2 Active EP2770066B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16158591.4A EP3093350B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP19180822.9A EP3572530B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11050108P 2008-10-31 2008-10-31
US12/503,318 US20100112571A1 (en) 2008-10-31 2009-07-15 Compositions and methods for detecting mutations in jak2 nucleic acid
EP09824031.0A EP2340315B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés de détection de mutations dans l acide nucléique jak2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP09824031.0A Division EP2340315B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés de détection de mutations dans l acide nucléique jak2

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16158591.4A Division EP3093350B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP19180822.9A Division EP3572530B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2

Publications (3)

Publication Number Publication Date
EP2770066A2 EP2770066A2 (fr) 2014-08-27
EP2770066A3 true EP2770066A3 (fr) 2014-09-03
EP2770066B1 EP2770066B1 (fr) 2016-03-09

Family

ID=42129212

Family Applications (4)

Application Number Title Priority Date Filing Date
EP14161006.3A Active EP2770066B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2
EP19180822.9A Active EP3572530B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP16158591.4A Active EP3093350B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP09824031.0A Active EP2340315B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés de détection de mutations dans l acide nucléique jak2

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP19180822.9A Active EP3572530B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP16158591.4A Active EP3093350B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés pour détecter des mutations dans un acide nucléique jak2
EP09824031.0A Active EP2340315B1 (fr) 2008-10-31 2009-10-22 Compositions et procédés de détection de mutations dans l acide nucléique jak2

Country Status (4)

Country Link
US (1) US20100112571A1 (fr)
EP (4) EP2770066B1 (fr)
JP (3) JP6017136B2 (fr)
WO (1) WO2010051214A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512948B2 (en) 2008-10-31 2013-08-20 Quest Diagnostics Investments Incorporated Compositions and methods for detecting mutations in JAK2 nucleic acid
US20100112571A1 (en) * 2008-10-31 2010-05-06 Quest Diagnostics Investments Incorporated Compositions and methods for detecting mutations in jak2 nucleic acid
WO2014068072A1 (fr) * 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, évaluation et traitement de la thrombocytémie essentielle associée à une résistance aux inhibiteurs de jak2
WO2017018385A1 (fr) * 2015-07-24 2017-02-02 公立大学法人名古屋市立大学 Méthode d'aide au diagnostic d'affections de type myélofibrose, méthode d'aide à la prédiction du pronostic, méthode de surveillance d'un effet thérapeutique, et marqueur et dispositif utilisés pour ce faire
JP7456739B2 (ja) * 2019-08-30 2024-03-27 東洋鋼鈑株式会社 骨髄増殖性腫瘍に関連する遺伝子変異評価用キット
CN114302967A (zh) * 2019-08-30 2022-04-08 东洋钢钣株式会社 用于评价骨髓增殖性肿瘤相关基因突变的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639611A (en) * 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
EP0560890B1 (fr) * 1990-11-28 2005-01-12 Ludwig Institute For Cancer Research Nouvelle kinase de tyrosine proteique
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
CN1477703A (zh) * 2002-08-02 2004-02-25 ǧס������ҵ��ʽ���� 焊球组件及其生产方法，形成焊块的方法
CA2621261C (fr) * 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US20070224598A1 (en) * 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20100112571A1 (en) * 2008-10-31 2010-05-06 Quest Diagnostics Investments Incorporated Compositions and methods for detecting mutations in jak2 nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BESSES CARLOS ET AL: "JAK2 mutations at exon 12 and 14 in polycythemia vera and idiopathic erythrocytosis: Incidence and correlation with clinical characteristics", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11, part 1, 1 November 2007 (2007-11-01), pages 746A, XP009157146, ISSN: 0006-4971 *
ELENA ALBIERO ET AL: "A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders", AMERICAN JOURNAL OF HEMATOLOGY, vol. 83, no. 7, 1 July 2008 (2008-07-01), pages 603 - 604, XP055131400, ISSN: 0361-8609, DOI: 10.1002/ajh.21116 *
LEE TAI-SUNG ET AL: "Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations", BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. 1, 10 September 2009 (2009-09-10), pages 58, XP021058180, ISSN: 1472-6807, DOI: 10.1186/1472-6807-9-58 *
M INAMI ET AL: "Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia", LEUKEMIA, vol. 22, no. 1, 1 January 2008 (2008-01-01), pages 216 - 216, XP055131403, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2404953 *
MA WANLONG ET AL: "Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias", JOURNAL OF MOLECULAR DIAGNOSTICS, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, BETHESDA, MD, US, vol. 11, no. 1, 1 January 2009 (2009-01-01), pages 49 - 53, XP009115055, ISSN: 1525-1578, DOI: 10.2353/JMOLDX.2009.080114 *
MA WANLONG ET AL: "Splice Variant JAK2 Transcript Deleting Exon 14 in Patients with Chronic Myeloproliferative Neoplasms", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 22, 1 November 2009 (2009-11-01), XP009179314, ISSN: 0006-4971 *
SMITH C A ET AL: "The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 39, no. 6, 1 June 2008 (2008-06-01), pages 795 - 810, XP022693901, ISSN: 0046-8177, [retrieved on 20080603], DOI: 10.1016/J.HUMPATH.2008.02.004 *
TEFFERI A: "JAK and MPL mutations in myeloid malignancies", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 49, no. 3, 1 March 2008 (2008-03-01), pages 388 - 397, XP009157130, ISSN: 1042-8194, DOI: 10.1080/10428190801895360 *
WANLONG MA ET AL: "JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms", PLOS ONE, vol. 5, no. 8, 13 August 2010 (2010-08-13), pages e12165, XP055131407, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0012165 *

Also Published As

Publication number Publication date
JP6145083B2 (ja) 2017-06-07
EP2340315A4 (fr) 2012-04-25
WO2010051214A8 (fr) 2013-06-06
EP3572530B1 (fr) 2023-03-01
JP6017136B2 (ja) 2016-10-26
EP3572530A2 (fr) 2019-11-27
EP3093350B1 (fr) 2019-06-19
WO2010051214A1 (fr) 2010-05-06
EP2340315A1 (fr) 2011-07-06
EP3572530A3 (fr) 2020-02-26
EP2770066A2 (fr) 2014-08-27
EP2770066B1 (fr) 2016-03-09
EP3093350A3 (fr) 2017-03-15
JP2015061531A (ja) 2015-04-02
EP3093350A2 (fr) 2016-11-16
JP2017070296A (ja) 2017-04-13
EP2340315B1 (fr) 2014-03-26
JP2012507291A (ja) 2012-03-29
US20100112571A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
WO2009073345A3 (fr) Dosage pour détecter des anomalies génétiques dans des acides nucléiques génomiques
WO2006131928A8 (fr) Nouvelles sequences de nucleotides et d'acides amines, leurs dosages et methodes d'utilisation en vue du diagnostic
HK1211624A1 (en) Methods for profiling and quantitating cell-free rna
EP2770066A3 (fr) Compositions et procédés pour détecter des mutations dans un acide nucléique JAK2
EP3831954A3 (fr) Procédés et compositions de profilage moléculaire pour le diagnostic de maladies
WO2008033427A3 (fr) Compositions et procédés de détection d'une maladie lysosomale
WO2010053587A3 (fr) Procédés de surveillance de maladies par analyse de séquence
WO2006050499A3 (fr) Dosage de detection en une seule etape
NZ601079A (en) Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
WO2008122670A3 (fr) Gène tnfrsf10b de susceptibilité au diabète chez l'homme
WO2011072177A3 (fr) Dosage de biomarqueurs pour le diagnostic et le classement des maladies cardiovasculaires
WO2008108803A3 (fr) Biocapteurs de cellules immunitaires et méthodes d'utilisation correspondantes
WO2005114190A3 (fr) Procedes pour identifier des marqueurs biologiques
WO2009134452A3 (fr) Analyse de diagnostic d'accouchement prématuré
WO2007070376A3 (fr) Diagnostic, pronostic et suivi de la progression du lupus erythemateux systemique par analyse de microreseaux de leucocytes sanguins
WO2007114986A3 (fr) Sondes coopératives et leurs procédés d'utilisation
WO2006128042A3 (fr) Procedes d'identification de mutations dans un acide nucleique
WO2006113245A3 (fr) Procedes de mesure des niveaux de glycane dans des proteines
WO2007039903A3 (fr) Nouveaux nucleotides et nouvelles sequences d'acides amines, et bioessais et procedes d'utilisation associes a des fins de diagnostic
WO2005072049A3 (fr) Expression differentielle de marqueurs en endometriose
WO2014117680A3 (fr) Utilisation des niveaux d'arn messager du gène trpc6 dans des cellules du sang périphérique pour le dépistage/diagnostic précoce de la démence sénile
WO2006020005A3 (fr) Diagnostic du transcriptome salivaire
WO2006119326A3 (fr) Compositions de sondes/amorces oligonucleotidiques et procedes de detection de polynucleotides
WO2005118403A3 (fr) Procedes pour detecter l'expression genique dans des cellules du sang peripherique et utilisations de ces procedes

Legal Events

Date Code Title Description
PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140321

AC Divisional application: reference to earlier application

Ref document number: 2340315

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101ALI20140731BHEP

Ipc: C12Q 1/68 20060101AFI20140731BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MA, WANLONG

Inventor name: ALBITAR, MAHER

R17P Request for examination filed (corrected)

Effective date: 20150227

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17Q First examination report despatched

Effective date: 20150428

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150812

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2340315

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 779592

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160315

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009036754

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160609

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160610

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 779592

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160709

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160711

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009036754

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

26N No opposition filed

Effective date: 20161212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20161022

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161102

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160309

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250902

Year of fee payment: 17